These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 31780779)
21. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933 [TBL] [Abstract][Full Text] [Related]
22. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. Parkinson CA; Gale D; Piskorz AM; Biggs H; Hodgkin C; Addley H; Freeman S; Moyle P; Sala E; Sayal K; Hosking K; Gounaris I; Jimenez-Linan M; Earl HM; Qian W; Rosenfeld N; Brenton JD PLoS Med; 2016 Dec; 13(12):e1002198. PubMed ID: 27997533 [TBL] [Abstract][Full Text] [Related]
23. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. Wojnarowicz PM; Oros KK; Quinn MC; Arcand SL; Gambaro K; Madore J; Birch AH; de Ladurantaye M; Rahimi K; Provencher DM; Mes-Masson AM; Greenwood CM; Tonin PN PLoS One; 2012; 7(9):e45484. PubMed ID: 23029043 [TBL] [Abstract][Full Text] [Related]
24. Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. Mittempergher L; Piskorz AM; Bosma AJ; Michaut M; Wisman GBA; Kluin RJC; Nieuwland M; Brugman W; van der Ven KJW; Marass F; Morris J; Rosenfeld N; Jimenez-Linan M; de Jong S; van der Zee AGJ; Brenton JD; Bernards R PLoS One; 2020; 15(7):e0235766. PubMed ID: 32639993 [TBL] [Abstract][Full Text] [Related]
25. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. Ghezelayagh TS; Pennington KP; Norquist BM; Khasnavis N; Radke MR; Kilgore MR; Garcia RL; Lee M; Katz R; Leslie KK; Risques RA; Swisher EM Gynecol Oncol; 2021 Mar; 160(3):786-792. PubMed ID: 33375991 [TBL] [Abstract][Full Text] [Related]
26. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype. Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568 [TBL] [Abstract][Full Text] [Related]
27. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer. Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698 [TBL] [Abstract][Full Text] [Related]
28. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression. Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428 [TBL] [Abstract][Full Text] [Related]
30. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755 [TBL] [Abstract][Full Text] [Related]
31. Expression signatures of TP53 mutations in serous ovarian cancers. Bernardini MQ; Baba T; Lee PS; Barnett JC; Sfakianos GP; Secord AA; Murphy SK; Iversen E; Marks JR; Berchuck A BMC Cancer; 2010 May; 10():237. PubMed ID: 20504346 [TBL] [Abstract][Full Text] [Related]
32. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Krimmel JD; Schmitt MW; Harrell MI; Agnew KJ; Kennedy SR; Emond MJ; Loeb LA; Swisher EM; Risques RA Proc Natl Acad Sci U S A; 2016 May; 113(21):6005-10. PubMed ID: 27152024 [TBL] [Abstract][Full Text] [Related]
33. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714 [TBL] [Abstract][Full Text] [Related]
34. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer. Zhang M; Zhuang G; Sun X; Shen Y; Wang W; Li Q; Di W Diagn Pathol; 2017 Feb; 12(1):16. PubMed ID: 28148293 [TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211 [TBL] [Abstract][Full Text] [Related]
36. miR-7 expression in serous ovarian carcinomas. Swiercz A; Chechlinska M; Kupryjanczyk J; Dansonka-Mieszkowska A; Rembiszewska A; Goryca K; Kulinczak M; Zajdel M; Sromek M; Siwicki JK Anticancer Res; 2015 Apr; 35(4):2423-9. PubMed ID: 25862909 [TBL] [Abstract][Full Text] [Related]
38. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern. Kim HN; Woo HY; DO SI; Kim HS In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396 [TBL] [Abstract][Full Text] [Related]
39. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937 [TBL] [Abstract][Full Text] [Related]